DNA vs. MRNA

Last updated Jun 3, 2026

DNA (Ginkgo Bioworks Holdings, Inc.) and MRNA (Moderna, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, DNA returned -52.72%/yr vs -25.22%/yr for MRNA. At a 0.35 correlation, their price movements are largely independent.

Performance

DNA vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DNA achieves a 12.27% return, which is significantly lower than MRNA's 54.76% return.

DNA

• 1D: 2.08%
• 1M: -3.81%
• YTD: 12.27%
• 6M: 8.61%
• 1Y: 30.86%
• 3Y*: -47.59%
• 5Y*: -52.72%
• 10Y*: —

MRNA

• 1D: -0.91%
• 1M: 0.60%
• YTD: 54.76%
• 6M: 89.69%
• 1Y: 68.72%
• 3Y*: -29.55%
• 5Y*: -25.22%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

DNA vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DNA Ginkgo Bioworks Holdings, Inc.	12.27%	-15.38%	-85.47%	0.00%	-79.66%	-17.89%
MRNA Moderna, Inc.	54.76%	-29.08%	-58.19%	-44.63%	-29.28%	56.86%

Correlation

The correlation between DNA and MRNA is 0.39, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.39
Correlation (3Y) Calculated over the trailing 3-year period	0.37
Correlation (5Y) Calculated over the trailing 5-year period	0.36
Correlation (All Time) Calculated using the full available price history since Apr 20, 2021	0.35

Fundamentals

Market Cap DNA : $555.73M MRNA : $18.03B
EPS DNA : -$5.40 MRNA : -$8.16
PS Ratio DNA : 4.32 MRNA : 8.03
PB Ratio DNA : 1.25 MRNA : 2.43
Total Revenue (TTM) DNA : $121.84M MRNA : $2.23B
Gross Profit (TTM) DNA : $99.27M MRNA : -$309.00M
EBITDA (TTM) DNA : -$218.90M MRNA : -$3.02B

Return for Risk

DNA vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA

DNA Risk / Return Rank: 53
DNA Sharpe Ratio Rank: 51
DNA Sortino Ratio Rank: 56
DNA Omega Ratio Rank: 55
DNA Calmar Ratio Rank: 52
DNA Martin Ratio Rank: 50

MRNA

MRNA Risk / Return Rank: 72
MRNA Sharpe Ratio Rank: 73
MRNA Sortino Ratio Rank: 73
MRNA Omega Ratio Rank: 68
MRNA Calmar Ratio Rank: 74
MRNA Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNA vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DNA	MRNA	Difference
Sharpe ratio Return per unit of total volatility	0.31	1.09	-0.77
Sortino ratio Return per unit of downside risk	1.14	1.93	-0.80
Omega ratio Gain probability vs. loss probability	1.14	1.22	-0.07
Calmar ratio Return relative to maximum drawdown	0.52	2.02	-1.50
Martin ratio Return relative to average drawdown	0.90	4.02	-3.12
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DNA vs. MRNA - Sharpe Ratio Comparison

The current DNA Sharpe Ratio is 0.31, which is lower than the MRNA Sharpe Ratio of 1.09. The chart below compares the historical Sharpe Ratios of DNA and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	DNA	MRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.31	1.09	-0.77
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.54	-0.38	-0.16
Sharpe Ratio (All Time) Calculated using the full available price history	-0.54	0.18	-0.72

Drawdowns

DNA vs. MRNA - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, roughly equal to the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for DNA and MRNA.

Drawdown Indicators

	DNA	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-99.10%	-95.38%	-3.72%
Max Drawdown (1Y) Largest decline over 1 year	-66.05%	-35.51%	-30.54%
Max Drawdown (3Y) Largest decline over 3 years	-94.72%	-86.58%	-8.14%
Max Drawdown (5Y) Largest decline over 5 years	-99.10%	-95.38%	-3.72%
Current Drawdown Current decline from peak	-98.44%	-90.58%	-7.86%
Average Drawdown Average peak-to-trough decline	-79.64%	-56.62%	-23.02%
Ulcer Index Depth and duration of drawdowns from previous peaks	38.15%	17.87%	+20.28%

Volatility

DNA vs. MRNA - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 23.46% compared to Moderna, Inc. (MRNA) at 17.07%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than MRNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DNA	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.46%	17.07%	+6.39%
Volatility (6M) Calculated over the trailing 6-month period	70.34%	48.11%	+22.23%
Volatility (1Y) Calculated over the trailing 1-year period	98.67%	63.55%	+35.12%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	97.66%	66.32%	+31.34%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.48%	71.89%	+24.59%

Dividends

DNA vs. MRNA - Dividend Comparison

Neither DNA nor MRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both DNA and MRNA in my portfolio?

DNA and MRNA have a correlation of 0.39, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DNA or MRNA?

DNA has higher volatility (23.46%) compared to MRNA (17.07%). In terms of maximum drawdown, DNA dropped -99.10% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (1.09 vs 0.31), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.